The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development and production. This upward trend is further supported by advancements in manufacturing technology, increased research and development efforts, and a wave of new product launches by major industry players.
LAS VEGAS, Feb. 5, 2025 /PRNewswire/ -- DelveInsight's Biologics Drug Substance Manufacturing Market Insights [https://www.delveinsight.com/report-store/biologics-drug-substance-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr] report provides the current and forecast market analysis, individual leading biologics drug substance manufacturing companies' market shares, challenges, biologics drug substance manufacturing market drivers, barriers, trends, and key market biologics drug substance manufacturing companies in the market.
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg [https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg]
Key Takeaways from the Biologics Drug Substance Manufacturing Market Report
-- As per DelveInsight estimates, North America is anticipated to dominate
the global biologics drug substance manufacturing market during the
forecast period.
-- In the biologics type segment of the biologics drug substance
manufacturing market, the monoclonal antibodies category accounted for
the largest market share in 2024.
-- Notable biologics drug substance manufacturing companies such as Lonza,
Pfizer Inc., Catalent, Inc., Boehringer Ingelheim International GmbH,
Samsung Biologics, WuXi AppTec, Thermo Fisher Scientific Inc., Asahi
Kasei Corporation, Recipharm AB, Evotec, Novo Nordisk A/S, Siegfried
Holding AG, Enzene Biosciences Ltd., Forge Biologics, BeiGene LTD.,
FUJIFILM Holdings Corporation, TOYOBO CO., LTD., AJINOMOTO CO., INC.,
Biocon, Eurofins Scientific, and several others, are currently operating
in the biologics drug substance manufacturing market.
-- In September 2024, Samsung Biologics launched biologics' innovative
development platforms - S-AfuCHOTM and S-OptiChargeTM. S-AfuCHOTM is an
innovative cell line platform designed to produce fucosylated
antibodies, which demonstrate enhanced antibody-dependent cellular
cytotoxicity (ADCC) activity, leading to increased therapeutic efficacy.
In parallel, S-OptiChargeTM serves as an upstream process platform
capable of modulating a molecule's charge variant distribution.
-- In June 2024, Bionova Scientific, a U.S.-based biologics contract
development and manufacturing organization (CDMO) within the Asahi Kasei
Group, announced plans to establish a new facility in Texas. This
expansion aims to enhance its capabilities in biologics manufacturing
and support the growing demand for biopharmaceutical products.
-- In January 2024, Enzene Biosciences announced the launch of its first
manufacturing site in the United States, situated in Hopewell, near
Princeton, New Jersey. The company has leased 54,000 square feet of
space to accommodate multiple manufacturing lines utilizing its
continuous manufacturing technology platform, EnzeneX(TM). This facility
is designed to integrate Enzene's patented EnzeneX(TM) platform,
allowing for efficient and scalable production of biologics.
To read more about the latest highlights related to the biologics drug substance manufacturing market, get a snapshot of the key highlights entailed in the Global Biologics Drug Substance Manufacturing Market Report [https://www.delveinsight.com/sample-request/biologics-drug-substance-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Biologics Drug Substance Manufacturing Overview
Biologics drug substance manufacturing is a highly complex and tightly regulated process that involves the production of therapeutic proteins, monoclonal antibodies, vaccines, and other biologics derived from living cells. Unlike small molecule drugs, biologics are large, structurally intricate molecules produced using cell culture systems such as Chinese Hamster Ovary (CHO) cells, bacterial or yeast expression systems. The process typically involves upstream processing, where cell lines are cultivated in bioreactors under controlled conditions to maximize yield, followed by downstream processing, which includes purification steps such as chromatography and ultrafiltration to ensure high purity and efficacy. Stringent quality control and adherence to Good Manufacturing Practices (GMP) are crucial at every stage to ensure consistency, safety, and efficacy of the final drug substance.
Scaling up biologics manufacturing from lab-scale to commercial production presents significant challenges, including maintaining cell viability, optimizing yields, and ensuring batch-to-batch consistency. Advances in single-use bioreactors, process intensification, and automation have helped streamline manufacturing while improving flexibility and cost efficiency. Regulatory agencies such as the FDA and EMA impose strict guidelines on manufacturing practices, requiring extensive characterization, validation, and risk mitigation strategies to minimize variability and contamination risks. As biologics continue to dominate the pharmaceutical market, innovations in continuous manufacturing, cell-free synthesis, and AI-driven process optimization are shaping the future of biologics drug substance manufacturing, making it more scalable, efficient, and accessible for global patient needs.
Biologics Drug Substance Manufacturing Market Insights
In 2024, North America held the largest share of the biologics drug substance manufacturing market among all regions. This growth is primarily fueled by a rising patient population affected by chronic diseases like cancer and diabetes. Additionally, the increasing geriatric population, which is more prone to such conditions, further accelerates market expansion. Key contributors to this trend include heightened research and development efforts by leading companies and the growing adoption of biologic drugs.
To strengthen their market presence, major industry players are actively establishing biologics manufacturing facilities in the region. For example, in July 2024, BeiGene Ltd. inaugurated its flagship U.S. facility in Hopewell, New Jersey, within the Princeton West Innovation Campus. This advanced site integrates state-of-the-art biologics manufacturing with a clinical research and development center, reinforcing BeiGene's position as a leader in oncology innovation. Spanning approximately 400,000 square feet, the facility is designed for commercial-scale biologic drug production and allows for future expansion. Such developments are expected to further propel market growth in North America.
To know more about why North America is leading the market growth in the biologics drug substance manufacturing market, get a snapshot of the Biologics Drug Substance Manufacturing Market Outlook [https://www.delveinsight.com/sample-request/biologics-drug-substance-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Biologics Drug Substance Manufacturing Market Dynamics [https://www.delveinsight.com/report-store/biologics-drug-substance-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
The biologics drug substance manufacturing market is experiencing rapid growth, driven by increasing demand for biologic therapies, including monoclonal antibodies, cell and gene therapies, and recombinant proteins. With the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions, pharmaceutical companies are investing heavily in biologics development and production. Unlike small-molecule drugs, biologics require complex manufacturing processes involving living cells, stringent quality controls, and specialized infrastructure, making the market highly competitive and capital-intensive.
A key trend in the market is the growing reliance on contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). Many biotech companies, particularly small and mid-sized firms, lack the resources to build and operate large-scale biologics manufacturing facilities. As a result, they partner with specialized CDMOs that offer end-to-end services, from cell line development to commercial-scale production. This has led to increased investments in CDMO capacity expansion, with major players enhancing their capabilities in advanced bioprocessing technologies, single-use systems, and continuous manufacturing.
Regulatory dynamics also play a crucial role in shaping the market. Regulatory agencies like the FDA and EMA have stringent guidelines for biologics manufacturing, ensuring product safety, efficacy, and consistency. Recent advancements in biosimilar regulations have further influenced the market, creating opportunities for companies to develop cost-effective alternatives to expensive biologics. However, navigating regulatory requirements remains a challenge, requiring significant expertise in Good Manufacturing Practices (GMP), process validation, and analytical characterization.
Technological innovations are transforming the biologics manufacturing landscape. Advances in cell culture techniques, bioreactor design, and automation are improving productivity, scalability, and cost efficiency. The adoption of artificial intelligence (AI) and machine learning in bioprocess optimization is further streamlining manufacturing workflows, reducing batch failures, and enhancing yield. Additionally, the shift toward personalized medicine is driving demand for flexible manufacturing solutions, including modular facilities and decentralized production models.
Despite the strong growth potential, challenges such as high production costs, supply chain constraints, and talent shortages persist. The complexity of biologics manufacturing requires a highly skilled workforce, and the industry faces a shortage of professionals with expertise in bioprocess engineering and regulatory compliance. Companies are addressing these challenges by investing in workforce development programs, expanding automation, and improving supply chain resilience through strategic partnerships. As the biologics market continues to expand, addressing these challenges will be crucial for sustaining long-term growth and innovation.
Get a sneak peek at the biologics drug substance manufacturing market dynamics @ Biologics Drug Substance Manufacturing Market Dynamics Analysis [https://www.delveinsight.com/sample-request/biologics-drug-substance-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Report Metrics Details Coverage Global Study Period 2022-2032 Biologics Drug Substance Manufacturing Market CAGR ~11% Biologics Drug Substance Manufacturing Market Size by 2032 USD 968 Million Key Biologics Drug Substance Manufacturing Companies Lonza, Pfizer Inc., Catalent, Inc., Boehringer Ingelheim International GmbH, Samsung Biologics, WuXi AppTec, Thermo Fisher Scientific Inc., Asahi Kasei Corporation, Recipharm AB, Evotec, Novo Nordisk A/S, Siegfried Holding AG, Enzene Biosciences Ltd., Forge Biologics, BeiGene LTD., FUJIFILM Holdings Corporation, TOYOBO CO., LTD., AJINOMOTO CO., INC., Biocon, Eurofins Scientific, among others
Biologics Drug Substance Manufacturing Market Assessment
-- Biologics Drug Substance Manufacturing Market Segmentation
-- Biologics Drug Substance Manufacturing Market Segmentation By
Biologics Type: Monoclonal Antibodies, Recombinant Protein, Growth
Hormones, Vaccines, Therapeutic Enzyme, and Others
-- Biologics Drug Substance Manufacturing Market Segmentation By
Manufacturing: In-house and Outsourced
-- Biologics Drug Substance Manufacturing Market Segmentation By
Production Source: Cell Line/Cell Culture, Genetic Engineering, and
Microbial Fermentation
-- Biologics Drug Substance Manufacturing Market Segmentation By
Geography: North America, Europe, Asia-Pacific, and Rest of World
-- Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's
Views, Analyst's View
Which MedTech key players in the biologics drug substance manufacturing market are set to emerge as the trendsetter explore @ Biologics Drug Substance Manufacturing Companies [https://www.delveinsight.com/sample-request/biologics-drug-substance-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Table of Contents
1 Biologics Drug Substance Manufacturing Market Report Introduction 2 Biologics Drug Substance Manufacturing Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Biologics Drug Substance Manufacturing Market Key Factors Analysis 6 Biologics Drug Substance Manufacturing Market Porter's Five Forces Analysis 7 Biologics Drug Substance Manufacturing Market Layout 8 Biologics Drug Substance Manufacturing Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us
Interested in knowing the biologics drug substance manufacturing market by 2032? Click to get a snapshot of the Biologics Drug Substance Manufacturing Market Trends [https://www.delveinsight.com/sample-request/biologics-drug-substance-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Related Reports
Biologics Drug Substance Fill and Finish Manufacturing Market [https://www.delveinsight.com/report-store/biologics-drug-substance-fill-and-finish-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Biologics Drug Substance Fill and Finish Manufacturing Market Insight, Competitive Landscape, and Market Forecast - 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance fill and finish manufacturing companies, including JOINN Biologics, Pharmaron, Symbiosis Pharmaceutical Services, AGC Biologics, INCOG BioPharma Services, CPC, Eurofins Scientific, among others.
Biologics Contract Manufacturing Market [https://www.delveinsight.com/report-store/biologics-contract-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Biologics Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biologics contract manufacturing companies, including Boehringer Ingelheim, Catalent, Lonza, WuXi Biologics, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie, AGC Biologics, among others.
Contract Development Manufacturing Organization Market [https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Contract Development Manufacturing Organization Market Insights, Competitive Landscape, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CDMO companies, including Patheon (Thermo Fisher Scientific), Catalent,Inc, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., Inc, AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics, among others.
Biopharmaceuticals Contract Manufacturing Market [https://www.delveinsight.com/report-store/biopharmaceuticals-contract-manufacturing-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Biopharmaceuticals Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biopharmaceuticals contract manufacturing companies, including Boehringer Ingelheim International GmbH, Lonza, Rentschler Biopharma SE, BINEX Co., Ltd., INCOG BioPharma Service, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Novartis AG, ProBioGen AG, TOYOBO CO., LTD., Samsung Biologics, Thermo Fisher Scientific, Inc., AbbVie, Inc., WuXi Biologics, AGC Biologics, ADMA Biologics, Inc., Baxter BioPharma Solutions (Baxter), iBio., Catalent, Inc., Cambrex Corporation, Pfizer Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
info@delveinsight.com [mailto:info@delveinsight.com]
+14699457679
https://www.delveinsight.com/medical-devices [https://www.delveinsight.com/medical-devices]
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg [https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg]
View original content:https://www.prnewswire.co.uk/news-releases/global-biologics-drug-substance-manufacturing-market-to-exhibit-growth-at-a-cagr-of-11-by-2032--delveinsight-302368371.html [https://www.prnewswire.co.uk/news-releases/global-biologics-drug-substance-manufacturing-market-to-exhibit-growth-at-a-cagr-of-11-by-2032--delveinsight-302368371.html]
Photo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg DelveInsight Business Research, LLP